Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Abstract Background The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects. Here we present novel data from the ANANKE study in which a large cohort of SEA patients was treated for up to 96 weeks....

Full description

Bibliographic Details
Main Authors: Alessandra Vultaggio, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Maria D’Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Marco Benci, Silvia Boarino, Jan Walter Schroeder
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Respiratory Research
Subjects:
Benralizumab
Asthma
Eosinophils
Exacerbations
Long-term
Online Access:https://doi.org/10.1186/s12931-023-02439-w

Internet

https://doi.org/10.1186/s12931-023-02439-w

Similar Items